Can lurbinectedin cause fetal abnormalities?
Lurbinectedin is not recommended in pregnancy because it can harm a developing fetus. The drug’s labeling includes warnings that exposure during pregnancy may cause fetal harm and that women should use effective contraception during treatment and for a period after the last dose.[1]
What does the safety information say about pregnancy and birth defects?
The available safety guidance centers on the risk of fetal harm from maternal exposure. That means fetal abnormalities are a recognized concern, and pregnancy is treated as a high-risk scenario for anyone who could become pregnant while on lurbinectedin.[1]
If someone becomes pregnant while on lurbinectedin, what should they do?
If pregnancy occurs during treatment, patients should contact their treating oncology team right away to discuss immediate next steps and risk counseling. The key point in the safety information is that fetal harm is possible with exposure.[1]
Do we know how soon abnormalities could occur?
The warning is based on potential developmental risk from exposure rather than a specific “time window” listed for when abnormalities would appear. The practical takeaway is that any exposure during pregnancy is considered dangerous enough to drive pregnancy avoidance and contraception requirements.[1]
Does lurbinectedin also affect people trying to conceive (male patients)?
The pregnancy-risk language focuses on preventing fetal exposure. Many oncology regimens also include guidance for people who could father a child (contraception and timing after treatment), but the specific recommendations depend on the prescribing information.[1]
What alternatives are considered if pregnancy is planned or ongoing?
If pregnancy is planned or suspected, clinicians typically evaluate whether lurbinectedin can be delayed, replaced with another approach, or managed with alternative treatment strategies. The need to avoid fetal exposure is the main driver of these decisions, given the potential for fetal harm.[1]
Sources
- Drug information for lurbinectedin (Zepzelca) – pregnancy and fetal risk details